Immunizations
TRENTON, N.J. - Johnson & Johnson said Wednesday it is buying Holland's Crucell NV for about $2.41 billion, marking the American health care giant's latest effort to gain a big foothold in the coveted vaccine business.
AMSTERDAM - Johnson & Johnson said Friday it is in advanced talks to acquire Dutch biotech company Crucell NV for 1.75 billion ($2.29 billion), a deal that would boost the American health care product maker's vaccine business.
CHICAGO - Flu vaccination should be required for all doctors, nurses and other health workers, the nation's largest pediatricians' group says, calling it a long overdue step to protect patients.
WASHINGTON - Drug and medical device firm Abbott Laboratories said Friday it has abandoned plans to sell its vaccines unit, less than three months after exploring sales talks with rival companies.
More News
- NY legislators want chickens vaccinated
- Drug chains offering seasonal flu shots early
- Walgreen stores now selling seasonal flu shots
- Vaccine sales up 16 pct in 2009, still growing
- Dynavax posts 2Q loss, weighed down by expenses
- Merck pairs up with Chinese drugmaker Sinopharm
- Abbott considers selling vaccines business
- Britain bans doctor who linked autism to vaccine
- UK bans doctor who linked autism to vaccine
- UK bans doc who linked autism to vaccine
- FDA approves breakthrough cancer therapy Provenge
- Merck inks deal on tetanus, diphtheria vaccine
- Drug maker Novartis says 1Q profit up 49 percent
- Summary Box: Walgreen flu shots and revenue fell
- Glaxo, Pfizer agree to supply pneumonia vaccines
- BioSante cancer vaccine gets 'orphan drug' status
- Court to rule in military funeral protest case
- Court will hear case about vaccine side effects
- Panel recommends annual flu vaccinations for all
- Summary Box: FDA OKs Pfizer's updated kids vaccine
- Pfizer says FDA OKs updated infection vaccine
- Novartis gets US approval for meningitis vaccine
- Merck: Studies boost Gardasil for new uses
- Sanofi-Aventis Q4 profit up on swine flu vaccines
- GlaxoSmithKline Q4 profit up 66 pct
- UK medical panel rules against doctor over vaccine
- AstraZeneca to cut 8,000 jobs amid weak earnings
- Pfizer pares, refocuses research after Wyeth buy
- Mexico still waiting for most swine flu vaccines
- Merck spent $1.5M in 3Q lobbying on health reform
- Nasal swine flu vaccine recalled over potency
- Swine flu vaccine now plentiful in half the states
- Kids' Swine flu shots recalled; not strong enough
- 800,000 doses of kids' swine flu vaccine recalled
- WHO to monitor for flu outbreaks at Vancouver
